BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
52.80
+0.28 (0.53%)
At close: Nov 5, 2025, 4:00 PM EST
53.97
+1.17 (2.22%)
After-hours: Nov 5, 2025, 7:49 PM EST
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
$1,017,763
Profits / Employee
$171,190
Market Cap
10.14B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | 3,001 | 152 | 5.34% |
| Dec 31, 2018 | 2,849 | 268 | 10.38% |
| Dec 31, 2017 | 2,581 | 288 | 12.56% |
| Dec 31, 2016 | 2,293 | 135 | 6.26% |
| Dec 31, 2015 | 2,158 | 477 | 28.38% |
| Dec 31, 2014 | 1,681 | 340 | 25.35% |
| Dec 31, 2013 | 1,341 | 252 | 23.14% |
| Dec 31, 2012 | 1,089 | 87 | 8.68% |
| Dec 31, 2011 | 1,002 | 131 | 15.04% |
| Dec 31, 2010 | 871 | 151 | 20.97% |
| Dec 31, 2009 | 720 | 71 | 10.94% |
| Dec 31, 2008 | 649 | 124 | 23.62% |
| Dec 31, 2007 | 525 | 115 | 28.05% |
| Dec 31, 2006 | 410 | 96 | 30.57% |
| Dec 31, 2005 | 314 | -45 | -12.53% |
| Dec 31, 2004 | 359 | 87 | 31.99% |
| Dec 31, 2003 | 272 | 53 | 24.20% |
| Dec 31, 2002 | 219 | 3 | 1.39% |
| Dec 31, 2001 | 216 | 42 | 24.14% |
| Dec 31, 2000 | 174 | 25 | 16.78% |
| Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BMRN News
- 7 days ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
- 8 days ago - Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings - Benzinga
- 8 days ago - BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations - Seeking Alpha
- 9 days ago - BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - BioMarin Pharma plans to divest struggling gene therapy - Reuters
- 9 days ago - BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 14 days ago - BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET - PRNewsWire
- 5 weeks ago - BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks - Seeking Alpha